Forte Biosciences Inc (FBRX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-14
$76.990.00%
Close 2026-08-28 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-14
Research Workspace
Put FBRX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Primary pillar broken — Control operating expenses to manage cash burn: metric not reported.
View ThesisManagement screens strong on capital allocation, margins, the balance sheet, market reaction to earnings.
View ManagementThis stock is volatile — it swings about 2% on a typical day and fell roughly 56% in its worst 12-month stretch.
View RiskForte Biosciences must control operating expenses to manage cash burn to justify the price. Recent financial performance sits well below its industry cohort, indicating weak fundamentals. The company trades at a typical valuation compared to peers, with the price roughly in line with the growth forecast. The primary risk is the broken pillar of managing cash burn, as this metric is not reported. Peer multiples imply a price about 32% below where it trades. This read is provisional.
Trailing returns as of 2026-08-28. FBRX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 5 analysts currently covering FBRX (as of Aug 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare FBRX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| FBRX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put FBRX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Targeting celiac disease aligns with potential product development.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-08-28. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.